Abiopharma

🔍 Baweja Naveen (Executive)

Company: Alight, Inc. / Delaware (ALIT)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Acquired 733,235 shares of Class A Common Stock (Direct)
  Date: 2026-04-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 733,235.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 499,933 shares of Class A Common Stock (Direct)
  Date: 2026-04-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,233,168.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Acquired 1,250,000 shares of Performance Stock Units (Derivative)
  Date: 2026-04-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,250,000.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5

Footnotes:

• F1: Represents Restricted Stock Units ("RSUs") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan in connection with the Reporting Person's appointment as Chief Technology Officer. The RSUs are scheduled to vest 50% on April 29, 2027, 25% on April 29, 2028, and 25% on April 29, 2029.
• F2: Includes restricted stock units scheduled to vest in the future.
• F3: Represents Restricted Stock Units ("RSUs") scheduled to vest in approximately three equal installments on April 29, 2027, April 29, 2028 and April 29, 2029.
• F4: On April 29, 2026, the reporting person was granted 1,250,000 performance stock Units. Each performance stock unit represents a contingent right to receive one share of Alight, Inc.'s Class A Common Stock.
• F5: The performance stock units vest and become earned in up to 25% increments based on the achievement of specified stock price performance hurdles during a five-year performance period, beginning on April 1, 2026, and ending on December 31, 2030, and subject to service-based vesting conditions.